Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
Age
12 - 17 years
Sex
ALL
Healthy Volunteers
No
Research Site
Phoenix, Arizona, United States
Research Site
Fresno, California, United States
Research Site
Fullerton, California, United States
Research Site
Newport Beach, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
San Francisco, California, United States
Research Site
Centennial, Colorado, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Thornton, Colorado, United States
Start Date
September 1, 2010
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
May 18, 2016
1,653
ACTUAL participants
Placebo
DRUG
Zolmitriptan
DRUG
Zolmitriptan
DRUG
Zolmitriptan
DRUG
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions